Overview
Browse spinoutsLegal name
ROSA BIOTECH LIMITED
Region
South West England
Registered address
Unknown
Insolvency history
No
Spinout
Active
LTD
Company profile
Rosa Biotech Limited
Rosa Biotech | Biosensing & diagnostics
Rosa Biotech is redefining biosensing. We are addressing intractable challenges in early disease diagnosis and industrial biotechnology.
CRN
11781337
Founded
2019
Age
7
Company events
Reference milestones and recent Companies House filing stream events.
2 events
26 Nov
2024
Gazette Dissolved Voluntary
GazetteGAZ2(A) | Transaction MzQ0NDE2MjMwMWFkaXF6a2N4 | Paper/PDF filed
Published 22 Nov 2024 03:03
22 Jan
2019
Incorporated
InceptionCompany registered at Companies House
Spinout profile
5 entries
Company description
Rosa Biotech develops artificially intelligent biosensing tools based on nano-scale peptide barrels, with applications in industrial research and clinical diagnostics.
Rosa Biotech is redefining biosensing. We are enabling previously intractable challenges in early disease diagnosis and industrial biotechnology to be addressed accurately and at scale. Rosa's patent-pending technology builds upon and extends the pioneering protein design work of Prof. Dek Woolfson and his team at the University of Bristol's Synthetic Biology Research Centre, BrisSynBio. By combining this with advanced machine-learning techniques, Rosa offers a powerful platform capable of being trained to address numerous complex biosensing problems
Project impact
None yet
NA
Rosa Biotech
2019
Rosa Biotech
2019
Rosa Biotech
2019
Rosa Biotech
2019
ROSA BIOTECH LIMITED
2019
Public funding
1 award
First funded
2022
Funded years
2022
Age at first award
3 years
Projects
2022
Collaborative R&D
Lead participant
Developing a prototype device for point-of-care non-alcoholic fatty liver disease diagnostics
1 Apr 2022 to 30 Sep 2023
Awarded
£236,422
Total cost £337,745
Non-alcoholic fatty liver disease (NAFLD) is caused by fat accumulation in the liver and affects 20-30% of adults globally, ≈20% of whom progress to a more serious condition called non-alcoholic steatohepatitis (NASH). NASH-related liver damage is reversible, but only if diagnosed early. However, NASH diagnosis rates are extremely low, and for most patien...
Product types
Collaborative R&D